Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   AVICENNA JOURNAL OF MEDICAL BIOTECHNOLOGY (AJMB)   JULY-SEPTEMBER 2011 , Volume 3 , Number 3 (10); Page(s) 119 To 125.
 
Paper: 

COMPARATIVE EXPRESSION PROFILE OF ORPHAN RECEPTOR TYROSINE KINASE ROR1 IN IRANIAN PATIENTS WITH LYMPHOID AND MYELOID LEUKEMIAS

 
 
Author(s):  SHABANI MAHDI, ASGARIAN OMRAN HOSSEIN, FARSANGI MOHAMMAD HOJAT, VOSSOUGH PARVANEH, SHARIFIAN RAMAZAN A., TOUGHE GHOLAM R., RAZAVI SEYED MOHSEN, KHOSHNOODI JALAL, JEDDI TEHRANI MAHMOOD, RABBANI HODJATALLAH, SHOKRI FAZEL*
 
* SCHOOL OF PUBLIC HEALTH, TEHRAN UNIVERSITY OF MEDICAL SCIENCES, TEHRAN, IRAN
 
Abstract: 

It has recently been shown that ROR1, a member of the receptor tyrosine kinase family, is overexpressed in leukemic B cells of Chronic Lymphocytic Leukemia (CLL) and a subset of Acute Lymphoblastic Leukemia (ALL). In this comparative study the expression profile of ROR1 mRNA was investigated in Iranian patients with CLL and Acute Myelogenous Leukemia (AML) and the results were compared with those previously reported in our Iranian ALL patients. RT-PCR was performed on bone marrow and/or peripheral blood samples of 84 CLL and 12 AML patients. CLL samples were classified into im-munoglobulin heavy chain variable region (IGHV) gene mutated (n=55) and unmutated (n=29) and also indolent (n=42) and progressive (n=39) subtypes. ROR1 expression was identified in 94% of our CLL patients, but none of the AML patients expressed ROR1. No significant differences were observed be-tween different CLL subtypes for ROR1 expression. Taken together the present data and our previous results on ROR1 expression in ALL, our findings propose ROR1 as a tumor-associated antigen overexpressed in a large proportion of lymphoid (CLL and ALL), but not myeloid (AML) leukemias. Expression of ROR1 seems to be associated to lineage and differentiation stages of leukemic cells with a potential implication for immunotherapy.

 
Keyword(s): ACUTE MYELOGENOUS LEUKEMIA, CHRONIC LYMPHOCYTIC LEUKEMIA, ROR1, RT-PCR
 
 
References: 
  • ندارد
  •  
 
Cite:
APA: Copy

SHABANI, M., & ASGARIAN OMRAN, H., & FARSANGI, M., & VOSSOUGH, P., & SHARIFIAN, R., & TOUGHE, G., & RAZAVI, S., & KHOSHNOODI, J., & JEDDI TEHRANI, M., & RABBANI, H., & SHOKRI, F. (2011). COMPARATIVE EXPRESSION PROFILE OF ORPHAN RECEPTOR TYROSINE KINASE ROR1 IN IRANIAN PATIENTS WITH LYMPHOID AND MYELOID LEUKEMIAS. AVICENNA JOURNAL OF MEDICAL BIOTECHNOLOGY (AJMB), 3(3 (10)), 119-125. https://www.sid.ir/en/journal/ViewPaper.aspx?id=208312



Vancouver: Copy

SHABANI MAHDI, ASGARIAN OMRAN HOSSEIN, FARSANGI MOHAMMAD HOJAT, VOSSOUGH PARVANEH, SHARIFIAN RAMAZAN A., TOUGHE GHOLAM R., RAZAVI SEYED MOHSEN, KHOSHNOODI JALAL, JEDDI TEHRANI MAHMOOD, RABBANI HODJATALLAH, SHOKRI FAZEL. COMPARATIVE EXPRESSION PROFILE OF ORPHAN RECEPTOR TYROSINE KINASE ROR1 IN IRANIAN PATIENTS WITH LYMPHOID AND MYELOID LEUKEMIAS. AVICENNA JOURNAL OF MEDICAL BIOTECHNOLOGY (AJMB). 2011 [cited 2021April20];3(3 (10)):119-125. Available from: https://www.sid.ir/en/journal/ViewPaper.aspx?id=208312



IEEE: Copy

SHABANI, M., ASGARIAN OMRAN, H., FARSANGI, M., VOSSOUGH, P., SHARIFIAN, R., TOUGHE, G., RAZAVI, S., KHOSHNOODI, J., JEDDI TEHRANI, M., RABBANI, H., SHOKRI, F., 2011. COMPARATIVE EXPRESSION PROFILE OF ORPHAN RECEPTOR TYROSINE KINASE ROR1 IN IRANIAN PATIENTS WITH LYMPHOID AND MYELOID LEUKEMIAS. AVICENNA JOURNAL OF MEDICAL BIOTECHNOLOGY (AJMB), [online] 3(3 (10)), pp.119-125. Available: <https://www.sid.ir/en/journal/ViewPaper.aspx?id=208312>.



 
  pdf-File
Yearly Visit 94
 
Latest on Blog
Enter SID Blog